Abstract
Primary plasma cell leukemia (pPCL) is the most aggressive form of the plasma cell (PC) malignancy, multiple myeloma (MM). It has been commonly associated with the presence of a chromosome translocation involving the immunoglobulin heavy chain (IgH) locus on 14q32, that is t (11;14). Results from early phase clinical trials utilizing the selective Bcl-2 inhibitor, venetoclax, as a single agent in patients with relapsed MM have had remarkable efficacy among patients with t (11;14) abnormality. The present case demonstrates the ability of a combination regimen incorporating Bcl-2 inhibition with daratumumab, bortezomib, venetoclax, and dexamethasone to induce a rapid and very deep hematologic response in a pPCL patient with t (11;14), even in a setting of very refractory disease. This case highlights the need to further study Bcl-2 inhibition-based therapy as an option for therapy in patients with pPCL with t (11;14).
Original language | English (US) |
---|---|
Pages (from-to) | 215-217 |
Number of pages | 3 |
Journal | European Journal of Haematology |
Volume | 100 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2018 |
Keywords
- Bcl-2 inhibition
- Venetoclax
- plasma cell leukemia
ASJC Scopus subject areas
- Hematology